Intervacc is trading at €0.08, down 13.43%, with no clear explanation identified for the August 10, 2026 decline.
- No reported company-specific announcement directly explained the selloff; broader markets were essentially flat.
- Latest surfaced developments were an EMA application seeking 12-month Strangvac immunity labeling and New Zealand vaccine distribution, neither explicitly linked to the decline.
- Further review is warranted if delayed disclosures emerge.